197 related articles for article (PubMed ID: 36557069)
21. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.
Deniger DC; Yu J; Huls MH; Figliola MJ; Mi T; Maiti SN; Widhopf GF; Hurton LV; Thokala R; Singh H; Olivares S; Champlin RE; Wierda WG; Kipps TJ; Cooper LJ
PLoS One; 2015; 10(6):e0128151. PubMed ID: 26030772
[TBL] [Abstract][Full Text] [Related]
22. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers.
Zhang S; Chen L; Wang-Rodriguez J; Zhang L; Cui B; Frankel W; Wu R; Kipps TJ
Am J Pathol; 2012 Dec; 181(6):1903-10. PubMed ID: 23041612
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of the Expression of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) in Chronic Lymphocytic Leukemia.
Yikilmaz AŞ; Bakanay ŞM; Avcı DN; Akinci S; Falay M; Özet G; Dilek İ
Int J Hematol Oncol Stem Cell Res; 2023 Jan; 17(1):39-47. PubMed ID: 37638287
[No Abstract] [Full Text] [Related]
24. ROR1 is highly expressed in circulating tumor cells and promotes invasion of pancreatic cancer.
Xu GL; Shen J; Xu YH; Wang WS; Ni CF
Mol Med Rep; 2018 Dec; 18(6):5087-5094. PubMed ID: 30272313
[TBL] [Abstract][Full Text] [Related]
25. Functional and clinical significance of ROR1 in lung adenocarcinoma.
Schiavone G; Epistolio S; Martin V; Molinari F; Barizzi J; Mazzucchelli L; Frattini M; Wannesson L
BMC Cancer; 2020 Nov; 20(1):1085. PubMed ID: 33172431
[TBL] [Abstract][Full Text] [Related]
26. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
27. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.
Berger C; Sommermeyer D; Hudecek M; Berger M; Balakrishnan A; Paszkiewicz PJ; Kosasih PL; Rader C; Riddell SR
Cancer Immunol Res; 2015 Feb; 3(2):206-16. PubMed ID: 25355068
[TBL] [Abstract][Full Text] [Related]
28. A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo.
Yin Z; Mao Y; Zhang N; Su Y; Zhu J; Tong H; Zhang H
Biomed Pharmacother; 2019 Nov; 119():109420. PubMed ID: 31536932
[TBL] [Abstract][Full Text] [Related]
29. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.
Islam SS; Uddin M; Noman ASM; Akter H; Dity NJ; Basiruzzman M; Uddin F; Ahsan J; Annoor S; Alaiya AA; Al-Alwan M; Yeger H; Farhat WA
EBioMedicine; 2019 May; 43():211-224. PubMed ID: 31085100
[TBL] [Abstract][Full Text] [Related]
30. The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
Semin Cancer Biol; 2014 Dec; 29():21-31. PubMed ID: 25068995
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of receptor tyrosine kinase-like orphan receptor 1 in preeclampsia placenta inhibits human trophoblast cell proliferation, migration, and invasion by PI3K/AKT/mTOR pathway accommodation.
Chen J; Yue C; Xu J; Zhan Y; Zhao H; Li Y; Ye Y
Placenta; 2019 Jul; 82():17-24. PubMed ID: 31174622
[TBL] [Abstract][Full Text] [Related]
32. ROR1 and ROR2 expression in pancreatic cancer.
Liu D; Sharbeen G; Phillips P; ; Ford CE
BMC Cancer; 2021 Nov; 21(1):1199. PubMed ID: 34763666
[TBL] [Abstract][Full Text] [Related]
33. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.
Dave H; Anver MR; Butcher DO; Brown P; Khan J; Wayne AS; Baskar S; Rader C
PLoS One; 2012; 7(12):e52655. PubMed ID: 23285131
[TBL] [Abstract][Full Text] [Related]
34. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.
Zhang S; Chen L; Cui B; Chuang HY; Yu J; Wang-Rodriguez J; Tang L; Chen G; Basak GW; Kipps TJ
PLoS One; 2012; 7(3):e31127. PubMed ID: 22403610
[TBL] [Abstract][Full Text] [Related]
35. Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1.
Cao J; Wang X; Dai T; Wu Y; Zhang M; Cao R; Zhang R; Wang G; Jiang R; Zhou BP; Shi J; Kang T
Theranostics; 2018; 8(10):2739-2751. PubMed ID: 29774072
[No Abstract] [Full Text] [Related]
36. miR-379-5p inhibits proliferation and invasion of the endometrial cancer cells by inhibiting expression of ROR1.
Liang M; Chen H; Min J
Acta Biochim Pol; 2021 Jun; 68(4):659-665. PubMed ID: 34115460
[TBL] [Abstract][Full Text] [Related]
37. The signaling pathways activated by ROR1 in cancer.
Quezada MJ; Lopez-Bergami P
Cell Signal; 2023 Apr; 104():110588. PubMed ID: 36621728
[TBL] [Abstract][Full Text] [Related]
38. Do patients with oral squamous cell carcinoma express receptor tyrosine kinase-like orphan receptor 1? Results of an observational study.
Nema S; Kallianpur S; Kumar A; Nema R; Vishwakarma S; Nema SK
J Oral Maxillofac Pathol; 2021; 25(1):105-109. PubMed ID: 34349419
[TBL] [Abstract][Full Text] [Related]
39. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.
Li P; Harris D; Liu Z; Liu J; Keating M; Estrov Z
PLoS One; 2010 Jul; 5(7):e11859. PubMed ID: 20686606
[TBL] [Abstract][Full Text] [Related]
40. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.
Henry C; Llamosas E; Knipprath-Meszaros A; Schoetzau A; Obermann E; Fuenfschilling M; Caduff R; Fink D; Hacker N; Ward R; Heinzelmann-Schwarz V; Ford C
Oncotarget; 2015 Nov; 6(37):40310-26. PubMed ID: 26515598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
